Pacific Northwest Chapter of AACE Annual Meeting

Seattle, WA US
October 14, 2017

Welcome, and thank you for attending the Pacific Northwest-AACE 2017 Annual Meeting.

The Pacific Northwest Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Endocrinologists, advanced practice clinicians and other healthcare professionals interested in the treatment of endocrine disease living or working in Alaska, Hawaii, Idaho, Montana, Oregon, Wyoming & Washington

Learning Objectives

  1. Understand the mechanism of action of denosumab
  2. Appreciate what happens to BMD, BTM and fracture risk when denosumab is stopped
  3. Understand new agents in development
  4. Understand the results of recently published clinical trials
  5. Explain how discussed articles affect our practice
  6. Discuss the safety of novel diabetes medications
  7. Identify the types of endocrine dysfunction which can be induced by immunotherapy
  8. Review the management of immunotherapy induced endocrine dysfunction
  9. Review the mechanisms and treatments of targeted therapy associated metabolic dysfunction
  10. Explore therapeutic options in immune modulator mediated endocrine disease associated with oncologic treatments
  11. Identify metabolic bone disease uncommon presentations
  12. Review the evaluation of nonsurgical hypoparathyroidism
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 3.75 AMA
  • 3.75 Attendance
Course opens: 
10/14/2017
Course expires: 
10/14/2018
Event starts: 
10/14/2017 - 7:00am
Event ends: 
10/14/2017 - 12:15pm
Cost:
$0.00
Rating: 
4

Program Agenda

* Please click the program's title to view each presentation.

7:00 - 8:00 AMRegistration and Breakfast
8:00 - 9:00 AMManaging Osteoporosis in 2017
Nelson B. Watts, MD, FACP, CCD, MACE
Objectives:
  1. Understand the mechanism of action of denosumab
  2. Appreciate what happens to BMD, BTM and fracture risk when denosumab is stopped
  3. Understand new agents in development
9:00 - 10:00 AMThe Best of the Past Year from JCEM, Diabetes Care, and Endo Practice 
Mahnaz Mellati, MD
Objectives:
  1. Understand the results of recently published clinical trials
  2. Explain how discussed articles affect our practice
  3. Discuss the safety of novel diabetes medications
10:00 - 10:30 AMBreak
10:30 - 11:30 AMEndocrine Care of Oncology Patients 
Conor Best, MD
Objectives:
  1. Identify the types of endocrine dysfunction which can be induced by immunotherapy
  2. Review the management of immunotherapy induced endocrine dysfunction
  3. Review the mechanisms and treatments of targeted therapy associated metabolic dysfunction
11:30 - 12:15 PMPatient Presentations: Conundrums and challenges in practice 
Lindsay Collins, MD; Jennifer Rosenbaum, MD, MEd;
Darius Schneider, MD, PhD; Kathryn Weaver, MD

Objectives:
  1. Explore therapeutic options in immune modulator mediated endocrine disease associated with oncologic treatments
  2. Know the indications for bisphosphonate treatment in patients with cancer
  3. Understand the relationship between bisphosphonate usage and atypical femur fractures.
Washington State Convention Center
705 Pike St
Seattle, WA 98101
United States

Conor Best, MD

Assistant Professor

Endocrine Neoplasia & Hormonal Disorders

University of Texas M.D. Anderson Cancer Center

Houston, TX

Lindsay Collins, MD

Endocrinology Fellow

University of Washington

Seattle, WA

Mahnaz Mellati, MD

The Polyclinic

Seattle, WA

Jennifer Rosenbaum MD, MEd

Fellow in the Department of Metabolism and Endocrinology

University of Washington

School of Medicine

Seattle, WA

Darius A. Schneider, MD, PhD

Fellow in Metabolism, Endocrinology and Nutrition

University of Washington

School of Medicine

Seattle, WA

Nelson B. Watts MD, FACP, MACE, CCD

Director, Mercy Health Osteoporosis and Bone Health Services

Cincinnati OH

Kathryn Weaver, MD

Endocrinology Fellow

University of Washington

Department of Medicine

Division of Metabolism, Endocrinology & Nutrition

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 3.75 AMA
  • 3.75 Attendance

Accreditation Period

Course opens: 
10/14/2017
Course expires: 
10/14/2018

Price

Cost:
$0.00
Please login or register to take this course.